Previous close | 2.3000 |
Open | 2.2200 |
Bid | 2.1700 |
Ask | 2.4100 |
Strike | 105.00 |
Expiry date | 2023-06-16 |
Day's range | 2.2200 - 2.2200 |
Contract range | N/A |
Volume | |
Open interest | 587 |
Moderna (NASDAQ: MRNA) helped some investors make a fortune over the past few years. The stock has climbed more than 400% since March 2020 -- that's when the company's coronavirus vaccine program gained traction. Recently, though, investors have worried about Moderna's post-pandemic revenue, and that's weighed on share performance.
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
Key Insights Given the large stake in the stock by institutions, Moderna's stock price might be vulnerable to their...